Francesco Marchesi, Irene Terrenato, Elena Papa, Martina Tomassi, Paolo Falcucci, Svitlana Gumenyuk, Francesca Palombi, Francesco Pisani, Daniela Renzi, Atelda Romano, Antonio Spadea, Giulia Regazzo, Maria Giulia Rizzo, Mafalda De Rienzo, Claudio Ripellino, Simona Sgromo, Caterina Viggiani, Eleonora Ponte, Ramy Kayal, Iole Cordone, Maria Laura Foddai, Andrea Mengarelli
Data about biosimilar Peg-filgrastim (bioPEG) in autologous stem cell transplant (ASCT) are still scarce. The aim of this study has been to assess efficacy and safety of bioPEG among lymphoma and myeloma patients undergoing ASCT, comparing these data with historical controls receiving other G-CSFs. Furthermore, an economic evaluation has been included to estimate the savings by using bioPEG. This is a prospective cohort study comparing lymphoma and myeloma patients undergoing ASCT and receiving bioPEG (n = 73) with three historical consecutive cohorts collected retrospectively who received other G-CSFs (Lenograstim - Leno - n = 101, biosimilar Filgrastim - bioFIL n = 392, and originator Peg-filgrastim - oriPEG n = 60)...
January 8, 2024: Annals of Hematology